Training improves glaucoma-induced visual field defects

Article

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial.

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial published in JAMA Ophthalmology. A new rehabilitation treatment option for such patients may involve behavioural computer-based, online-controlled vision training.

Behavioural vision training has been shown to improve visual fields in hemianopia and optic nerve damage. For this prospective, double-blind, randomized, placebo-controlled clinical trial, researchers gathered a volunteer sample of patients with glaucoma in an ambulatory care and home training setting.

Patients were a mean age of 61.7 years, all with stable visual fields and well-controlled IOPs. Interventions consisted of computer-based vision restoration training for glaucoma (n = 15) or visual discrimination placebo training in the intact visual field (n = 15).

Vision restoration training brought about significant detection accuracy gains in high-resolution perimetry (P = 0.007) not found with white-on-white or blue-on-yellow perimetry. In addition, Pre- to post-differences after training were greater compared with placebo in all perimetry tests (P = 0.02 for high-resolution perimetry; P = 0.04 for both white-on-white and for blue-on-yellow). All results were independent of eye movements.

Vision restoration training for glaucoma but not placebo led to a faster reaction time (P = 0.009). Patients' vision-related quality of life was unaffected, but patients' health-related quality-of-life mental health domain increased in both the vision restoration training and placebo groups.

To view the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.